This study aimed to assess the hepatoprotective efficacy of quercetin against hepatotoxicity induced by cyclophosphamide in a rat model. A total of 28 male Wister albino rats (Rattus norvegicus), with body weights ranging from 195.5 to 198.2 g and approximately three months of age, were randomized into four different groups: the untreated Control group received no interventions; the CYP group was treated with an intraperitoneal injection of cyclophosphamide at a dose of 200 mg/BW; the Qt group received an oral administration of quercetin at 100 mg/kg BW daily for ten days; and the combined (Qt+CYP) group received quercetin orally for ten days, followed by a cyclophosphamide injection on the tenth day. Various biochemical markers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and liver glutathione (GSH), and malondialdehyde (MDA), were analyzed, in addition to body weight and prothrombin time. The Untreated Control group exhibited baseline levels for all assessed markers. In contrast, the CYP group showed elevated levels of ALT, AST, ALP, and MDA, coupled with a decrease in GSH. Notably, the Qt+CYP group demonstrated a statistically significant reduction (P<0.05) in ALT, AST, ALP, and MDA levels, as well as an increase in GSH and prothrombin time, when compared to the CYP group. No significant differences in body weight were observed across all groups (P<0.05). The results of the study indicate that quercetin has the potential to be used as a hepatoprotective agent, protecting liver tissues from the cytotoxic effects of cyclophosphamide.